News
-
GH Research announced that it has submitted its response to a clinical hold of an IND for the company’s GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression. The FDA cited “Insufficient information to… Read more . . .
-
CDMO Kindeva has announced an agreement with Canadian company Rocket Science Health (RSH) for development of RSH’s “Olfactory Delivery Device,” which is designed for high deposition of drug to the olfactory clefts. Kindeva, which acquired nasal… Read more . . .
-
Lupin announced that it has signed an agreement with Sino Universal Pharmaceuticals for commercialization of Lupin’s tiotropium dry powder inhaler in China for the treatment of COPD. Per the agreement, Sino Universal will obtain marketing… Read more . . .
-
Milestone Pharmaceuticals says that it completed a Type A meeting with the FDA and subsequently submitted its response to the agency’s complete response letter regarding Milestone’s NDA for Cardamyst etripamil nasal spray for the treatment of… Read more . . .
-
Insmed has announced that a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension met its primary endpoint, demonstrating a 35% reduction from baseline in pulmonary vascular resistance. The company said… Read more . . .
-
Startup Mosanna Therapeutics announced that it has closed a $80 million Series A financing that will fund Phase 2 development of the company’s MOS118 nasal spray for the treatment of obstructive sleep apnea. Mosanna also announced the… Read more . . .
-
Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma’s ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The… Read more . . .
-
Leyden Laboratories has announced a €20 million venture debt financing deal with the European Investment Bank, with funds intended to support development of Leyden Labs’ antiviral nasal sprays, including PanFlu. The investment falls under the… Read more . . .
-
According to Cessatech, the Phase 2/3 Pediatric Study 0202 of the company’s CT001 sufentanil / ketamine nasal spray in children with severe pain met its primary endpoint, with more than half of patients reporting pain… Read more . . .
-
RDD Europe 2025, which took place in Estoril, Portugal May 6-9, welcomed approximately 490 delegates and 70 exhibitors from around the world to a meeting that focused on overcoming complex problems in order to advance inhaled… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK